Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LDHD drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LDHD Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View LDHD Products |
| Gene Delivery | LDHD Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View LDHD Products |
| Benchmark Ab | Anti-LDHD Recombinant Antibody Recombinant positive control for assay validation. |
View LDHD Products |
| Validator | LDHD siRNA Set For knockdown verification. |
View LDHD Products |
| Related Target A | LDHA (L-Lactate Dehydrogenase A) Essential for counter-screening to ensure D-isomer specificity. |
View LDHA Products |
| Related Target B | URAT1 (SLC22A12) Transporter involved in D-lactate-induced urate retention and gout pathways. |
View URAT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Selectivity (D- vs L-form) | High-purity recombinant LDHD and LDHA panels strictly verified by mass spectrometry. |
| Mitochondrial Localization / Conformation | Full-length sequence-verified expression preserving native-like fold. |
| Lack of Controls | Clinical benchmark antibodies and validated siRNA included. |
| False Positives | Endotoxin-controlled preparation (<1.0 EU/µg) to prevent cell-based assay toxicity. |
Live LDHD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LDHD therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule inhibitors and enzyme modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting D-lactate accumulation in the tumor microenvironment and metabolic syndromes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Oncology (Tumor Metabolism) | Selectivity Assay (Need high-purity LDHD vs LDHA/B proteins) |
| Gene Therapy / Replacement | Rare Disease Consortia | D-Lactic Acidosis, Metabolic Disorders | Overexpression Validation (Need Lentivirus for Stable Cell Lines) |
| Diagnostic / Biomarker Abs | Diagnostic Developers | Hyperuricemia, Gout, Gut Dysbiosis | High-affinity Antigen (Need Sequence Verified WT Protein) |